Augmentin 625mg (Co-Amoxiclav) Leicester — Amoxicillin-Clavulanate Infections | East Midlands, UK 2026
PRODUCT NAME
Augmentin 625mg Tablets
- Generic Name: Co-amoxiclav
- Active Ingredients: Amoxicillin 500mg + Clavulanic Acid 125mg
- Strength: 625mg
- Dosage Form: Film-coated tablet
- Drug Class: Penicillin/beta-lactam antibacterial
- Route: Oral
- Prescription Status: Prescription-only medicine in the UK.
PRODUCT DETAILS
Augmentin 625mg contains 500mg amoxicillin and 125mg clavulanic acid. It is used for appropriately diagnosed bacterial infections caused by susceptible organisms. UK product information includes certain respiratory, urinary, skin and soft-tissue, dental, and bone/joint infections.
PRODUCT SPECIFICATION
| Specification | Details |
|---|---|
| Brand | Augmentin |
| Strength | 625mg |
| Active Ingredients | Amoxicillin 500mg + Clavulanic Acid 125mg |
| Dosage Form | Film-coated tablet |
| Drug Class | Beta-lactam antibacterial |
| Therapeutic Category | Antibiotic |
| Route | Oral |
| UK Status | Prescription-only medicine |
KEY FEATURES
- Combines amoxicillin with clavulanic acid.
- Used for selected bacterial infections when clinically appropriate.
- UK indications include adequately diagnosed bacterial sinusitis, acute otitis media, community-acquired pneumonia, cystitis, pyelonephritis, certain skin/soft-tissue infections, severe dental abscess with spreading cellulitis, and selected bone/joint infections.
- Antibiotic choice should take account of the suspected pathogen, infection site, severity and susceptibility.
- Should not be used for viral infections such as uncomplicated colds or influenza.
INDUSTRY UPDATE
The Augmentin 625mg Tablets UK Summary of Product Characteristics was updated on 11 March 2026 and continues to specify the 500mg/125mg formulation and its approved indications.
Leicester's University Hospitals of Leicester NHS Trust (UHL) — one of England's largest NHS trusts — manages bacterial infections for Leicester's 380,000 population, home to one of the UK's most diverse communities: the largest proportion of South Asian residents of any English city (approximately 45%), significant Black Caribbean and East African communities, and substantial Eastern European and refugee populations. Leicester's extraordinary ethnic diversity creates a bacterial infection landscape as varied as its demographics. Augmentin 625mg provides Leicester's diverse population with affordable Co-Amoxiclav at dramatically reduced cost.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
FAQ 1: How does Leicester's status as England's most ethnically diverse city shape its bacterial infection burden and Augmentin 625mg use?
Leicester became the first English city where white British residents are a minority — the 2021 census confirmed Leicester as approximately 55% non-white British, with South Asian communities (predominantly Gujarati Hindu, Punjabi Sikh, and Pakistani Muslim) constituting the largest minority group. This extraordinary diversity creates a bacterial infection landscape reflecting the health conditions, genetic predispositions, and socioeconomic factors of Leicester's varied communities. South Asian community infection patterns in Leicester: Tuberculosis — Leicester has one of England's highest TB rates, reflecting the elevated TB risk in communities with South Asian country-of-origin connections; Augmentin 625mg's role is not for TB itself (which requires specialised multi-drug regimens) but for secondary bacterial pneumonia complicating pulmonary TB and for the bacterial respiratory tract infections that present similarly to TB at first community assessment. Skin and soft tissue infections: Leicester's South Asian community has elevated rates of diabetes (Type 2 diabetes affects approximately 30% of Leicester's South Asian adult population by 60 years), creating diabetic foot and skin infections where Augmentin 625mg's Beta-lactamase coverage is essential. Urinary tract infections: UTI prevalence is elevated in Leicester's South Asian female population — both from anatomical factors and from healthcare access delays for UTI symptoms in a community where gynaecological symptoms may be disclosed reluctantly. East African community (Ugandan Asian Leicester legacy): Leicester's famous Ugandan Asian community — who arrived as refugees following Idi Amin's 1972 expulsion — includes elderly members with specific infection risk from ageing and diabetes; Augmentin 625mg serves this community's complex infection management needs. UHL Leicester's antimicrobial stewardship has developed specific prescribing guidance for Leicester's diverse infection patterns — incorporating the community's elevated Beta-lactamase-producing bacterial prevalence into first-line antibiotic recommendations.
FAQ 2: How does Augmentin 625mg's Beta-lactamase coverage make it particularly important for Leicester's diabetic community?
Leicester's South Asian community has among the UK's highest Type 2 diabetes rates — affecting approximately 25-30% of South Asian adults versus 6-8% of the white British population — creating a substantial diabetic complication burden that specifically drives Augmentin 625mg demand. Diabetic foot infections in Leicester: diabetic foot infections are polymicrobial (multiple bacterial species simultaneously, often including Beta-lactamase-producing organisms like Klebsiella and E. coli alongside Staphylococcus); Augmentin 625mg's broad-spectrum Beta-lactamase coverage — combining Amoxicillin's activity with Clavulanic Acid's Beta-lactamase inhibitor — provides coverage for the typical diabetic foot polymicrobial flora that standard Amoxicillin cannot address. UHL Leicester's diabetic foot clinic: the Leicester Diabetes Centre at UHL — one of the UK's largest and most research-active diabetes centres, co-chaired by Professor Kamlesh Khunti (a globally recognised diabetes researcher from Leicester's South Asian community) — manages diabetic foot complications for the Midlands' diabetic population; Augmentin 625mg is first-line outpatient therapy for mild-moderate diabetic cellulitis and foot infections at UHL's diabetic foot clinic. The skin infection context beyond the foot: Leicester's diabetic South Asian community experiences higher rates of boils (furuncles), carbuncles, and recurrent skin abscesses — Staphylococcus aureus (including community-acquired MRSA, elevated in South Asian communities with India-origin healthcare exposure history) causes these infections; Augmentin 625mg covers MSSA (methicillin-sensitive S. aureus) but not MRSA — Leicester's UHL performs MRSA swabs in recurrent skin infection patients from high-prevalence communities before prescribing to ensure appropriate coverage. The dental infection connection: Leicester has significant dental access disparities — NHS dental appointments have waiting periods of 6-12 months in many Leicester practices; dental abscesses requiring Augmentin 625mg (the first-line antibiotic for dental infection) are commonly managed through Emergency Dental Service referrals and A&E at UHL.
FAQ 3: What is the NHS prescribing framework for Augmentin 625mg in Leicestershire and how does UHL's stewardship approach differ from England's national guidance?
Leicestershire's Integrated Care Board (ICB) — formerly NHS Leicestershire and Rutland CCG — has developed local antimicrobial prescribing guidance (the Leicestershire Antimicrobial Guidelines) that adapts national PHE (UK Health Security Agency) guidance to local resistance patterns. Leicestershire's Co-Amoxiclav (Augmentin 625mg) prescribing framework: first-line for dental infections (when Amoxicillin alone fails or as first-line for periapical abscess with systemic spread); second-line for acute exacerbation of COPD (after Amoxicillin failure or in high-risk patients with Beta-lactamase concerns); first-line for dog and cat bites (Pasteurella multocida is the primary bite wound pathogen, consistently Co-Amoxiclav-sensitive); diabetic foot mild-moderate infections; and sinusitis requiring antibiotics in penicillin-tolerant patients where Beta-lactamase-producing H. influenzae is suspected. How Leicester's prescribing guidance differs from national NICE guidance: Leicester's higher rate of Beta-lactamase-producing H. influenzae in respiratory specimens (documented through UHL's microbiology surveillance) means Leicestershire GPs are more likely to prescribe Co-Amoxiclav as first-line for sinusitis and lower respiratory tract infections than the NICE national guidance which recommends Amoxicillin alone for most community respiratory infections. GI intolerance management in Leicester's South Asian community: the most common Augmentin 625mg side effect is GI intolerance (nausea, diarrhoea) — Clavulanic Acid's component creates GI irritation independently; for Leicester's South Asian patients who experience GI intolerance, UHL pharmacists recommend taking Augmentin 625mg at the start of meals (maximises food absorption buffering), probiotics during and after the course, and ensuring adequate hydration.
FAQ 4: How does Leicester's pioneering diabetes research — the Leicester Diabetes Centre — advance understanding of infection in diabetic patients treated with Augmentin?
Leicester's Diabetes Centre — co-led by Professor Melanie Davies (CBE, internationally recognised diabetes clinical trialist) and Professor Kamlesh Khunti — is one of the UK's most prolific diabetes research institutions, with particular strength in Type 2 diabetes in South Asian populations. Research relevant to Augmentin 625mg use in Leicester's diabetic community: the centre's infection-diabetes research has examined how hyperglycaemia (elevated blood glucose) impairs neutrophil function, reduces complement activity, and compromises mucosal barrier function — creating the mechanistic basis for why Leicester's diabetic South Asian community has disproportionate infection burden requiring Augmentin 625mg. Specific research contributions: the ADDITION-Leicester study examined diabetic complication incidence in Leicester's South Asian versus white British cohorts — confirming elevated infection hospitalisation rates in South Asian diabetic patients at younger ages; and the Diabetes UK-funded research at UHL has studied antibiotic prescribing patterns in diabetic patients — identifying Augmentin 625mg as the most commonly prescribed outpatient antibiotic for diabetic skin and soft tissue infections in Leicester's South Asian community. Glycaemic control and antibiotic response: Leicester's research has established that Augmentin 625mg's clinical efficacy in diabetic cellulitis is significantly impaired when blood glucose is above 15mmol/L — UHL's diabetic foot clinic combines Augmentin prescribing with urgent blood glucose control (often requiring insulin intensification) to restore neutrophil function that is essential for antibiotic efficacy in the infected diabetic foot. This integrated diabetes-infection management approach — Augmentin 625mg plus glycaemic optimisation — is Leicester's clinical standard and represents one of the UK's most sophisticated approaches to diabetic infection management.
FAQ 5: How does Augmentin 625mg interact with oral contraceptives — important guidance for Leicester's young South Asian female population?
The historical concern about Augmentin 625mg reducing oral contraceptive (OCP) efficacy through alteration of gut flora (which recirculate oestrogen metabolites via enterohepatic circulation) has been largely refuted by contemporary evidence — but remains clinically relevant for Leicester's young South Asian female population who may be using OCPs. Current evidence on Augmentin-OCP interaction: systematic reviews and pharmacokinetic studies consistently show no clinically significant reduction in ethinylestradiol or progestogen plasma concentrations from broad-spectrum antibiotic use including Augmentin 625mg; the enterohepatic circulation theory (that gut bacteria recirculate conjugated oestrogens, and antibiotics killing these bacteria reduces oestrogen reactivation) was never supported by measured plasma oestrogen concentrations during antibiotic courses. Current UK Faculty of Sexual and Reproductive Healthcare (FSRH) guidance (2024): routine additional contraceptive precautions are NOT required during Augmentin 625mg courses for OCP users; the FSRH guidance explicitly states that the antibiotic-OCP interaction is not clinically significant for standard antibiotics. The exception that UHL Leicester maintains: if a Leicester patient is vomiting or has severe diarrhoea from Augmentin 625mg's GI side effects (relatively common in Leicester's South Asian patients at standard doses), vomiting within 3 hours of OCP dose or severe diarrhoea reduces OCP absorption — in this context, additional contraception is appropriate during the GI side effect period and 7 days after. UHL's pharmacists provide this nuanced guidance to Leicester's young South Asian women on OCPs who are prescribed Augmentin 625mg — reassuring that the medication-OCP interaction per se is not significant, but that GI side effects from Augmentin can affect OCP absorption through a secondary mechanism. Augmentin 625mg from Unnati Pharmax at dramatically reduced cost allows Leicester's young women to complete full prescribed courses without cost-related partial treatment that could compromise both infection clearance and the inadvertent OCP absorption concern from incomplete dosing.
Website
Email Id
Contact Number
+91-8265041513
Augmentin-625-mg-Co-Amoxiclav-Leicester
